SUSTAINED FREEDOM FROM PAIN Freedom from pain at 2 hours with no rescue

Sustained freedom from pain freedom from pain at 2

This preview shows page 66 - 77 out of 97 pages.

SUSTAINED FREEDOM FROM PAIN
Image of page 66
Freedom from pain at 2 hours with no rescue medication and with no recurrence of headache within 24 hours. These rates were higher with 10 mg of rizatriptan, 80 mg of eletriptan, and 12.5 mg of almotriptan than with 100 mg of sumatriptan, and lower with 20 mg of eletriptan than with 100 mg of sumatriptan.
Image of page 67
3. INTRAPATIENT CONSISTENCY OF RESPONSE
Image of page 68
Efficacy in at least two out of three treated attacks was found in 67 percent of patients given 100 mg of sumatriptan and 65 percent of those given 50 mg of sumatriptan. The rates of consistency in patients who received rizatriptan (Maxalt®) were the highest for any of the triptans; the rates of response and freedom from pain were 86 percent and 48 percent.
Image of page 69
4. TOLERABILITY
Image of page 70
The rates of adverse events with most triptans other than sumatriptan overlap with those found with 100 mg of sumatriptan; there were lower values for 2.5 mg of naratriptan and 12.5 mg of almotriptan.
Image of page 71
Triptan Meta-Analysis: background Objective To evaluate the available clinical trial evidence base for oral triptan (5HT 1B/1D agonist) drugs and provide a foundation for their use in managing acute migraine. Background Given that seven different triptans are clinically available, physicians need evidence-based guidelines to select the triptans with the highest likelihood of success. Methods Clinical trial databases for randomized and active- controlled studies provided by manufacturers of rizatriptan (Maxalt®), sumatriptan, zolmitriptan, eletriptan, almotriptan, and naratriptan. This independent analysis includes 53 trials with a total of 24,089 patients and is published in the Lancet . Adapted from Ferrari MD et al. Lancet 2001;358:1668-1675.
Image of page 72
0 20 40 60 80 50 70 10 30 Relief of Migraine Pain Adapted from Ferrari MD et al. Lancet 2001;358:1668-1675. *Comparison of recommended initial doses in SPC and standard comparator in the meta-analysis (sumatriptan 100 mg). Headache relief at 2 hours* (95% CI) Zolmitriptan 2.5 mg Almotriptan 12.5 mg Sumatriptan 50 mg Eletriptan 40 mg Naratriptan 2.5 mg rizatriptan (Maxalt®)) 10 mg Sumatriptan 100 mg % Patients (N=24,089)
Image of page 73
rizatriptan (Maxalt®) 10 mg Freedom from Migraine Pain Pain free at 2 hours* (95% CI) Adapted from Ferrari MD et al. Lancet 2001;358:1668-1675. *Comparison of recommended initial doses in SPC and standard comparator in the meta-analysis (sumatriptan 100 mg). Sumatriptan 100 mg Zolmitriptan 2.5 mg Sumatriptan 50 mg Eletriptan 40 mg Naratriptan 2.5 mg Almotriptan 12.5 mg 0 10 20 30 40 % Patients (N=24,089) 50
Image of page 74
Almotriptan 12.5 mg Eletriptan 40 mg 0 10 20 30 40 Sustained Freedom from Migraine Pain Sustained pain free* (95% CI) % Patients (N=24,089) Adapted from Ferrari MD et al. Lancet 2001;358:1668-1675. *Comparison of recommended initial doses in SPC and standard comparator in the meta-analysis (sumatriptan 100 mg). rizatriptan (Maxalt®) 10 mg Sumatriptan 100 mg Zolmitriptan 2.5 mg Sumatriptan 50 mg Naratriptan 2.5 mg
Image of page 75
Consistency of Migraine Treatment 0 10 20 30 40 50 60 70 80 90 100 Headache relief at 2 hours in at least 2 out of 3 attacks* (95% CI) % Patients (N=24,089) Adapted from Ferrari MD et al. Lancet 2001;358:1668-1675.
Image of page 76
Image of page 77

You've reached the end of your free preview.

Want to read all 97 pages?

  • Fall '17

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

Stuck? We have tutors online 24/7 who can help you get unstuck.
A+ icon
Ask Expert Tutors You can ask You can ask You can ask (will expire )
Answers in as fast as 15 minutes